{"disease":{"id":"relapsed-or-refractory-ctcl","name":"relapsed or refractory ctcl"},"drugs":{"marketed":[{"drug_id":"denileukin-diftitox-cxdl","indication_name":"Relapsed or Refractory CTCL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LYMPHIR","generic_name":"DENILEUKIN DIFTITOX-CXDL","company_name":"CITIUS PHARMS","drug_phase":"marketed","molecular_target":"","drug_class":"CD25-directed Cytotoxin [EPC]","quality_score":34,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06485219","title":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT04362007","title":"A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}